| Aug 7 |
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
|
| Aug 1 |
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
|
| Jul 28 |
The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%
|
| Jun 17 |
We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth
|
| Jun 14 |
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
|
| Jun 13 |
Stoke Therapeutics files to sell 10.84M shares for holders
|
| Jun 3 |
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
|
